Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MolDX lists Signatera for recurrence testing in ovarian cancer

The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera among the assays covered for progression, recurrence, or relapse testing in ovarian cancer.

CMS MolDX